botensilimab   Click here for help

GtoPdb Ligand ID: 14590

Synonyms: AGEN-1181 | AGEN1181
Immunopharmacology Ligand
Compound class: Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
No information available.
Summary of Clinical Use Click here for help
Botensilimab (AGEN-11810) is being investigated in combination with other anti-cancer drugs in advanced solid tumours, with a focus on dual treatment with the anti-PD-1 checkpoint inhibitor balstilimab [2,6-7,10].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06346197 Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Phase 3 Interventional Centre Leon Berard
NCT06279130 Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations Phase 2/Phase 3 Interventional The Netherlands Cancer Institute
NCT06322108 Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) Phase 2 Interventional Immune Oncology Research Institute
NCT03860272 Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Phase 1 Interventional Agenus Inc. 3
NCT07152821 Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Phase 3 Interventional Canadian Cancer Trials Group The BATTMAN study was terminated in mid-2026 as the developer changed focus away from microsatellite stable metastatic colorectal cancer and towards microsatellite stable colon cancer.